Tocilizumab in COVID-19: A Double-Edged Sword?

Tocilizumab in COVID-19: A Double-Edged Sword?

<b>Background/Objectives:</b> SARS-CoV-2 was responsible for the global pandemic. Approximately 10–15% of patients with COVID-19 developed respiratory failure with adult acute respiratory distress syndrome (ARDS), which required treatment in the Intensive Care Unit (ICU). The cytokine st...

Full description

Saved in:
Bibliographic Details
Main Authors: Bartosz Kudliński, Jacek Zawadzki, Wiktoria Kulińska, Jagoda Kania, Magdalena Murkos, Marta Stolińska, Dominika Zgoła, Anna Noga, Paweł Nowak
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Biomedicines
Subjects:
COVID-19
SARS-CoV-2
tocilizumab
cytokines
steroids
NDM
Online Access:https://www.mdpi.com/2227-9059/12/12/2924
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/12/12/2924

Similar Items